Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−2.04 USD
−64.73 M USD
0.00 USD
21.04 M
About AN2 Therapeutics, Inc.
Sector
Industry
CEO
Eric Easom
Website
Headquarters
Menlo Park
Founded
2017
FIGI
BBG00QYLYBK4
AN2 Therapeutics, Inc. operates as a global health biopharmaceutical company. The firm focuses on modern biomedical and drug development to provide transformational medicines for patients suffering from infectious diseases. The company was founded by Eric Easom, George Harrison Talbot, Joseph S. Zakrzewski and Michael R.K. Alley and is headquartered in Menlo Park, CA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of ANTX is 1.36 USD — it has decreased by −2.86% in the past 24 hours. Watch AN2 Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange AN2 Therapeutics, Inc. stocks are traded under the ticker ANTX.
ANTX stock has risen by 1.49% compared to the previous week, the month change is a 7.94% rise, over the last year AN2 Therapeutics, Inc. has showed a −93.32% decrease.
We've gathered analysts' opinions on AN2 Therapeutics, Inc. future price: according to them, ANTX price has a max estimate of 5.00 USD and a min estimate of 1.00 USD. Watch ANTX chart and read a more detailed AN2 Therapeutics, Inc. stock forecast: see what analysts think of AN2 Therapeutics, Inc. and suggest that you do with its stocks.
ANTX reached its all-time high on May 16, 2022 with the price of 23.58 USD, and its all-time low was 0.87 USD and was reached on Aug 9, 2024. View more price dynamics on ANTX chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
ANTX stock is 5.97% volatile and has beta coefficient of 2.37. Track AN2 Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is AN2 Therapeutics, Inc. there?
Today AN2 Therapeutics, Inc. has the market capitalization of 40.64 M, it has increased by 4.48% over the last week.
Yes, you can track AN2 Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
AN2 Therapeutics, Inc. is going to release the next earnings report on Mar 27, 2025. Keep track of upcoming events with our Earnings Calendar.
ANTX earnings for the last quarter are −0.43 USD per share, whereas the estimation was −0.45 USD resulting in a 4.44% surprise. The estimated earnings for the next quarter are −0.27 USD per share. See more details about AN2 Therapeutics, Inc. earnings.
AN2 Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
ANTX net income for the last quarter is −12.75 M USD, while the quarter before that showed −14.44 M USD of net income which accounts for 11.69% change. Track more AN2 Therapeutics, Inc. financial stats to get the full picture.
No, ANTX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 26, 2024, the company has 41.00 employees. See our rating of the largest employees — is AN2 Therapeutics, Inc. on this list?
Like other stocks, ANTX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade AN2 Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So AN2 Therapeutics, Inc. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating AN2 Therapeutics, Inc. stock shows the sell signal. See more of AN2 Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.